CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biomea Fusion Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biomea Fusion Inc
1599 Industrial Road
Phone: (302) 658-7581p:302 658-7581 SAN CARLOS, CA  94070  United States Ticker: BMEABMEA
Business Summary
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director Rainer M.Erdtmann 62 3/25/2025 8/1/2017
Interim Chief Executive Officer, Director Michael J.Hitchcock 76 3/25/2025 3/1/2021
Lead Independent Director EricAguiar 64 3/1/2025 12/1/2020
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Biomea Fusion Inc
BMEA

General Information
Number of Employees: 37 (As of 6/30/2026)
Outstanding Shares: 72,483,852 (As of 7/31/2026)
Shareholders: 29
Stock Exchange: NASD
Fax Number: (302) 655-5049
Email Address: info@biomeafusion.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, August 20, 2026